We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
By Oliver Griffin
AstraZeneca PLC (AZN.LN) said on Thursday that the U.S. Food and Drug Administration has approved cancer-drug Tagrisso for the first-line treatment of patients with metastatic non-small cell lung cancer.
The pharmaceutical company said that the approval by the FDA is based on results from the phase-three Flaura trial, which were presented at the European Society of Medical Oncology 2017 Congress and published in the New England Journal of Medicine.
Write to Oliver Griffin at oliver.griffin@dowjones.com
(END) Dow Jones Newswires
April 19, 2018 02:30 ET (06:30 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions